BIG research at ASCO 2018 (June 1-5, Chicago, USA)

Intro text: 

- Monday 28 May 2018 -




Several abstracts with updates or follow-on analyses from BIG trials were selected for presentation at the upcoming ASCO Annual Meeting, which will take place from 1 to 5 June 2018 in Chicago.


Here is a peek at some of them.

APHINITY (BIG 4-11), of which the primary results were published in the New England Journal of Medicine in 2017,  reports one of its secondary analyses, namely patient-reported health-related quality of life (HRQoL). It is one of the largest HRQoL data sets available to date in HER2-positive early breast cancer.
Trial information: NCT01358877

ALTTO / NeoALTTO (BIG 2-06 / 1-06)
Trial information: NCT00898898 and NCT00553358

Dr Matteo Lambertini, research fellow at the Institut Jules Bordet, Brussels, Belgium, presents further analyses from the NeoALTTO and ALTTO trials that aimed to evaluate the outcome of pregnancies occurring during or following trastuzumab and/or lapatinib, as well as the prognostic effect of having a pregnancy in HER2-positive early breast cancer patients.

Dr Lambertini is one of the recipients of the 2018 Conquer Cancer Merit Awards, which support early-career oncology professionals who are first authors on selected abstracts. This award recognises their important research findings in their respective fields within the cancer care continuum. 

Other abstracts related to ALTTO and NeoALTTO:


SOLE (BIG 1-07): The study investigators report the results of molecular analyses performed on 499 primary tumour samples from the patients enrolled in the main trial. The primary results of SOLE were published in the Lancet in January 2018.
Trial information: NCT00553410


POSITIVE (BIG 8-13) / the BIG Time for Baby study
Dr Ann H. Partridge presents an update of the POSITIVE trial and its psycho-oncological companion study, which have both reached about half of their respective target accrual.
Trial information: NCT02308085

Other abstract related to POSITIVE:


TEXT and SOFT (BIG 3-02 / 2-02)
Researchers report their conclusions on distant recurrence-free interval (DRFI) after 8.5 years median follow-up.
Trial information: NCT00066690, NCT00066703


MA32 (BIG 5-11)
Trial information: NCT01101438

Every year, the ASCO Annual Meeting brings together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.